EUCTR2010-018454-13-DE进行中（未招募）不适用
A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®
aboratoires SMB S.A.0 个研究点目标入组 552 人开始时间: 2010年5月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 552
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study if they:
- •1. Have a confirmed diagnosis of CF based on the following: sweat chloride >40 mEq/L and/or genotype with two identifiable mutations consistent with CF and one or more clinical features consistent with CF;
- •2. Are aged = 12 years;
- •3. Have FEV1 = 40.0% of predicted;
- •4. Have experienced at least one treated PE in the previous 12 months prior to Screening;
- •5. Are on stable rhDNase treatment (2.5 mg via nebuliser once daily) for 3 months before Screening (only for the patients taking rhDNase during the study);
- •6. Have >80% and <120% compliance during the Run-In period;
- •7. Have signed a written informed consent form (or assent provided by the parent/guardian) and are willing and able to comply with all study procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be ineligible if one or more of the following statements are applicable:
- •1. Patient has experienced a treated PE, resolved or unresolved, within 1 month of being screened;
- •2. Patient has been hospitalised or has had changes in antimicrobial, anti inflammatory, corticosteroids or long-acting bronchodilator medications within 2 weeks of randomisation;
- •3. Patient has been taking any mucolytic drug except rhDNase within 2 weeks of randomisation;
- •4. Patient has a history of hemoptysis (> 30 cc) within 3 months of randomisation;
- •5. Patient has participated in another clinical study within 1 month of randomisation;
- •6. Patient is a smoker of >10 cigarettes/day (or equivalent) or having a smoking history of >10 pack years;
- •7. Patient has a history of drug, alcohol, or medication abuse within the past 12 months;
- •8. Patient is pregnant or breast-feeding;
- •9. Female patient is of child-bearing potential and they or their partner are not using an acceptable form of contraception (defined as the use of an intra-uterine device [IUD], a barrier method with spermicide, condoms, subdermal implants or oral contraceptives);
- •10. Patient has a history of malignancy within the past 5 years;
- •11. Patient has a history of lung transplantation, is planning to undergo a lung transplantation during the study period or is currently on a transplantation list;
- •12. Patient known to have, or at risk of contracting, human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C or tuberculosis;
- •13. Patients with a know hypersensitivity or intolerance of nacystelyn, acetylcysteine, lysine or lactose;
- •14. Patient has a condition/abnormality of baseline clinical laboratory results that, in the opinion of the Principal Investigator, would compromise the safety of the patient.
研究者
相似试验
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist TherapyEUCTR2010-022758-18-HUJanssen-Cilag International N.V.675
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-DEJanssen-Cilag International NV737
进行中（未招募）
不适用
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseModerately to severely active Crohn's diseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022759-42-HUJanssen-Cilag International N.V.612
进行中（未招募）
1 期
Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate CancerEUCTR2017-003295-31-HUPfizer Inc., 235 East 42nd Street, New York, NY 100171,037
进行中（未招募）
1 期
A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- andHigh-risk Pulmonary arterial hypertension (PAH) Patients.EUCTR2021-000199-12-ITACCELERON PHARMA INC.662